Lung cancer • 5: State of the art radiotherapy for lung cancer

Thorax

Volumn 58, Issue 5, 2003, Pages 447-452

  Price, A ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIEMETIC AGENT; ANTINEOPLASTIC AGENT; CISPLATIN; DNA TOPOISOMERASE; EPIDERMAL GROWTH FACTOR ANTAGONIST; ETOPOSIDE; GEMCITABINE; MITOMYCIN; NAVELBINE; PACLITAXEL; POISON; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEIN INHIBITOR; TAXANE DERIVATIVE; TIRAPAZAMINE; UNCLASSIFIED DRUG;

BEAM THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER PREVENTION; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; DOSE CALCULATION; HEALTH CARE DELIVERY; HUMAN; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; META ANALYSIS; MORBIDITY; POSTOPERATIVE CARE; PRIORITY JOURNAL; QUALITY OF LIFE; RADIATION DOSE; RADIATION DOSE FRACTIONATION; RADIATION INDUCED EMESIS; REVIEW; SKULL IRRADIATION; THORAX; TOXICITY; TREATMENT PLANNING; LUNG TUMOR; MULTIMODALITY CANCER THERAPY; PALLIATIVE THERAPY; SURVIVAL;

ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; COMBINED MODALITY THERAPY; HUMANS; LUNG NEOPLASMS; PALLIATIVE CARE; QUALITY OF LIFE; RADIOTHERAPY DOSAGE; SURVIVAL ANALYSIS;

EID: 0037690746     PISSN: 00406376     EISSN: None     Source Type: Journal    
DOI: 10.1136/thorax.58.5.447     Document Type: Review

References (80)

1. Erridge SC, Thomson CS, Davidson J, et al. Factors influencing the use of thoracic radiotherapy in lung cancer: an analysis of the 1995 Scottish Lung Cancer Audit. Clin Oncol 2003;14:219-27.
2. Auperin A, Arriagada R, Pignon JP, et al. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview. N Engl J Med 1999;341:476-84.
3. Pignon JP, Arriagada R, Ihde DC, et al. A meta-analysis of thoracic radiotherapy for small-cell lung cancer. N Engl J Med 1992;327:1618-24.
4. Rowell NP, Williams CJ. Radical radiotherapy for stage I/II non-small cell lung cancer in patients not sufficiently fit or declining surgery (medically inoperable) (Cochrane Review). Cochrane Database Systematic Reviews 2001;2: CD002935.
5. Saunders M, Dische S, Barrett A, et al. Continuous hyperfractionated accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small cell lung cancer: a randomised multicentre trial. Lancet 1997;350:161-5.
6. Perez CA, Pajak TF, Rubin P, et al. Long-term observations of the patterns of failure in patients with unresectable non-oat cell carcinoma of the lung treated with definitive radiotherapy. Report by the Radiation Therapy Oncology Group. Cancer 1987;59:1874-81.
7. Hayman JA, Martel MK, Ten Haken RK, et al. Dose escalation in non-small cell lung cancer using three-dimensional conformal radiation therapy: update of a phase I trial. J Clin Oncol 2001;19:127-36.
8. Maguire PD, Marks LB, Sibley GS, et al. 73.6 Gy and beyond: hyperfractionated, accelerated radiotherapy for non-small cell lung cancer. J Clin Oncol 2001;19:705-11.
9. Rosenzweig KE, Mychalczak B, Fuks Z, et al. Final report of the 70.2-Gy and 75.6-Gy dose levels of a phase I dose escalation study using three-dimensional conformal radiotherapy in the treatment of inoperable non-small cell lung cancer. Cancer J 2000;6:82-7.
10. Belderbos JS, de Jaeger K, Heemsbergen WD, et al. Interim analysis of a phase I/II dose escalation trial in non-small cell lung cancer (NSCLC) using three-dimensional conformal radiotherapy (3D-CRT). Int J Radiat Oncol Biol Phys 2001;51(Suppl 1):345.
11. Graham MV, Winter K, Purdy JA, et al. Preliminary results of a Radiation Therapy Oncology Group trial (RTOG 9311), a dose escalation study using 3D conformal radiation therapy in patients with inoperable non-small cell lung cancer. Int J Radiat Oncol Biol Phys 2001;51 (Suppl 1):19.
12. Krol AD, Aussems P, Noordijk EM, et al. Local irradiation alone for peripheral stage I lung cancer: could we omit the elective regional nodal irradiation? Int J Radiat Oncol Biol Phys 1996;34:297-302.
13. Mehta M, Scrimger R, Mackie R, et al. A new approach to dose escalation in non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2001;49:23-33.
14. Samson MJ, van Sornsen de Koste JR, De Boer HC, et al. An analysis of anatomic landmark mobility and setup deviations in radiotherapy for lung cancer. Int J Radiat Oncol Biol Phys 1999;43:827-32.
15. De Boer HC, van Sornsen de Koste JR, Senan S, et al. Analysis and reduction of 3D systematic and random setup errors during the simulation and treatment of lung cancer patients with CT-based external beam radiotherapy dose planning. Int J Radiat Oncol Biol Phys 2001;49:857-68.
16. Stevens CW, Munden RF, Starkschall G, et al. Lung tumor motion with respiration does not correlate with location, pulmonary function or chest wall motion. Int J Radiat Oncol Biol Phys 1999;45(Suppl):384.
17. van Sornsen de Koste JR, Lagerwaard FJ, Schuchhard S, et al. Dosimetric consequences of tumor mobility in radiotherapy of stage I non-small cell lung cancer - an analysis of data generated using 'slow' CT scans. Radiother Oncol 2001;61:93-9.
18. Barnes EA, Murray BR, Robinson DM, et al. Dosimetric evaluation of lung tumor immobilization using breath hold at deep inspiration. Int J Radiat Oncol Biol Phys 2001;50:1091-8.
19. Rosenzweig KE, Hanley J, Mah D, et al. The deep inspiration breath-hold technique in the treatment of inoperable non-small cell lung cancer. Int J Radiat Oncol Biol Phys 2000;48:81-7.
20. Shirato H, Shimuzu S, Kunieda T, et al. Physical aspects of a real-time tumor tracking system for gated radiotherapy. Int J Radiat Oncol Biol Phys 2000;48:1187-95.
21. Kubo HD, Len PM, Minohara S, et al. Breathing-synchronized radiotherapy program at the University of California Davis Cancer Center. Med Phys 2000;27:346-53.
22. MacManus MP, Wong K, Hicks RJ, et al. Early mortality after radical radiotherapy for non-small-cell lung cancer: comparison of PET-staged and conventionally staged cohorts treated at a large tertiary referral center. Int J Radiat Oncol Biol Phys 2002;52:351-61.
23. Erdi YE, Rosenzweig KE, Erdi AK, et al. Radiotherapy treatment planning for patients with non-small cell lung cancer using positron emission tomography (PET). Radiother Oncol 2002;62:51-60.
24. Rabnett TJ, Machtay M, Vines EF, et al. Factors predicting severe radiation pneumonitis in patients receiving definitive chemoradiation for lung cancer. Int J Radiat Oncol Biol Phys 2000;48:89-94.
25. Ohe Y, Yamamoto S, Suzuki K, et al. Risk factors of treatment-related death in chemotherapy and thoracic radiotherapy for lung cancer. Eur J Cancer 2001;37:54-63.
26. Kwa SL, Lebesque JV, Theuws JC, et al. Radiation pneumonitis as a function of mean lung dose: an analysis of pooled data of 540 patients. Int J Radiat Oncol Biol Phys 1998: 42:1-9.
27. Graham MV, Purdy JA, Emami B, et al. Clinical dose-volume histogram analysis for pneumonitis after 3D treatment for non-small cell lung cancer (NSCLC). Int J Radiat Oncol Biol Phys 1999;45:323-9.
28. Choi NC, Kanarek DJ. Toxicity of thoracic radiotherapy on pulmonary function in lung cancer. Lung Cancer 1994;10(Suppl 1):S219-30.
29. Abratt RP, Willcox PA. Changes in lung function and perfusion after irradiation in patients with lung cancer. Lung Cancer 1994;11:61-9.
30. Einstein DB, Rubin P, Okunieff P, et al. Recovery of pulmonary function in patients receiving thoracic radiotherapy for thoracic malignancies. Int J Radiat Oncol Biol Phys 2000;48[Suppl):131.
31. Werner-Wasik M, Pequignot E, Leeper D, et al. Predictors of severe esophagitis include use of concurrent chemotherapy, but not the length of irradiated esophagus: a multivariate analysis of patients with lung cancer treated with nonoperative therapy. Int J Radiat Oncol Biol Phys 2000;48:689-96.
32. Byhardt R, Scott C, Sause W, et al. Response, toxicity, failure patterns, and survival in five Radiation Therapy Oncology Group (RTOG) trials of sequential and/or concurrent chemotherapy and radiotherapy for locally advanced non-small-cell carcinoma of the lung. Int J Radiat Oncol Biol Phys 1998;42:469-78.
33. Hirota S, Tsujino K, Endo M, et al. Dosimetric predictors of radiation esophagitis in patients treated for non-small cell lung cancer with carboplatin/paclitaxel/radiotherapy. Int J Radiat Oncol Biol Phys 2001;51:291-5.
34. Maguire PD, Sibley GS, Zhou SM, et al. Clinical and dosimetric predictors of radiation-induced esophageal toxicity. Int J Radiat Oncol Biol Phys 1999;45:97-103.
35. Non-small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 1995;311:899-909.
36. Cullen MH, Billingham LJ, Woodroffe CM, et al. Mitomycin, ifosfamide, and cisplatin in unresectable non-small-cell lung cancer: effects on survival and quality of life. J Clin Oncol 1999;17:3188-94.
37. Sause W, Kolesar P, Taylor IV S, et al. Final results of phase III trial in regionally advanced unresectable non-small cell lung cancer. Chest 2000;117:358-64.
38. Furuse K, Fukuoka M, Kawahara M, et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol 1999;17:2692-9.
39. Curran WJ, Scott C, Langer C, et al. Phase III comparison of sequential vs concurrent chemoradiation for pts with unresected stage III non-small cell lung cancer (NSCLC): report of Radiation Therapy Oncology Group (RTOG) 9410. Lung Cancer 2000;29(Suppl 1):93.
40. Saunders M, Rojas A, Lyn BE, et al. Experience with dose escalation using CHARTWEL (continuous hyperfractionated accelerated radiotherapy weekend less) in non-small cell lung cancer. Br J Cancer 1998;78:1323-8.
41. Stuschke M, Thames HD. Hyperfractionated radiotherapy of human tumors: overview of the randomized clinical trials. Int J Radiat Oncol Biol Phys 1997;37:259-67.
42. Gregor A. Gemcitabine plus radiotherapy for non-small lung cancer. Semin Oncol 1997;24(Suppl 8):S39-41
43. Jeremic B, Shibamoto Y, Acimovic L, et al. Randomized trial of hyperfractionated radiation therapy with or without concurrent chemotherapy for stage III non-small cell lung cancer. J Clin Oncol 1995;13:452-8.
44. Brown JM. Therapeutic targets in radiotherapy. Int J Radiat Oncol Biol Phys 2001;49:319-26.
45. Schaafsma J, Coy P. The effect of radiotherapy on the survival of non-small cell lung cancer patients. Int J Radiat Oncol Biol Phys 1998;41:291-8.
46. Langendijk JA, Aaronson NK, de Jong JM, et al. Prospective study on quality of life before and after radical radiotherapy in non-small-cell lung cancer. J Clin Oncol 2001;19:2123-33.
47. PORT Meta-analysis Trialists Group. Postoperative radiotherapy for non-small cell lung cancer. Cochrane Database Systematic Reviews 2000;CD002142.
48. Machtay M, Lee JH, Shrager JB, et al. Risk of death from intercurrent disease is not excessively increased by modern postoperative radiotherapy for high-risk resected non-small-cell lung carcinoma. J Clin Oncol 2001;19:3912-7.
49. Lung Cancer Study Group. Effects of postoperative mediastinal radiation on completely resected stage II and III epidermoid cancer of the lung. N Engl J Med 1986;315:1377-81.
50. Mayer R, Smolle-Juettner FM, Szolar D, et al. Postoerative radiotherapy in radically resected non-small cell lung cancer. Chest 1997;112:954-9.
51. Depierre A, Milleron B, Moro-Sibilot D, et al. Preoperative chemotherapy followed by surgery compared with primary surgery in resectable stage I (except T1NO), II, and IIIa non-small-cell lung cancer. J Clin Oncol 2002;20:247-53.
52. Macbeth FR, Toy E, Coles B, et al. Palliative radiotherapy regimens for non-small cell lung cancer (Cochrane review). Cochrane Database Systematic Reviews 2002;2:CD002143.
53. Medical Research Council Lung Cancer Working Party. Randomized trial of palliative two-fraction versus more intensive 13-fraction radiotherapy for patients with inoperable non-small cell lung cancer and good performance status. Clin Oncol 1996;8:167-75.
54. Kaasa S, Thorud E, Host H, et al. A randomised study evaluating radiotherapy versus chemotherapy in patients with inoperable non-small cell lung cancer. Radiother Oncol 1988;11:7-13.
55. Gaze MN, Kelly CG, Kerr GR, et al. Fractionated thoracic radiotherapy gives better symptom relief in patients with non-small cell lung cancer. Eur J Cancer 2001;37(Suppl 6):S29.
56. Bezjak A, Dixon P, Brundage M, et al. Randomized study of single versus fractionated radiotherapy (RT) in hte palliation of non-small cell lung cancer; NCIC CTG SC. 15. Int J Radiat Oncol Biol Phys 2001;51 (Suppl 1):20.
57. Old SE, Gilligan D. Do prophylactic steroids and anti-emetics reduce the incidence of adverse symptoms after hypofractionated palliative chest radiotherapy for non-small cell lung cancer? Lung Cancer 2000;29(Suppl 1):169.
58. Devereux S, Hatton MQF, Macbeth FR. Immediate side effects of large fraction radiotherapy. Clin Oncol 1997;9:96-9.
59. Lupattelli M, Maranzano E, Bellavita R, et al. Short-course palliative radiotherapy in non-small-cell lung cancer: results of a prospective study. Am J Clin Oncol 2000;23:89-93.
60. Langendijk JA, ten Velde GP, Aaronson NK, et al. Quality of life after palliative radiotherapy in non-small cell lung cancer: a prospective study. Int J Radiat Oncol Biol Phys 2000;47;149-55.
61. Stout R, Barber P, Burr PA, et al. Clinical and quality of life outcomes in the first United Kingdom randomized trial of endobronchial brachytherapy (intraluminal radiotherapy) vs external beam radiotherapy in the palliative treatment of inoperable non-small cell lung cancer. Radiother Oncol 2000;56:323-7.
62. Langendijk H, de Jong JM, Tjwa M, et al. External irradiation versus external irradiation plus endobronchial brachytherapy in inoperable non-small cell lung cancer: a prospective randomized trial. Radiother Oncol 2001;58:257-68.
63. Huber RM, Fischer R, Hautmann H, et al. Does additional brachytherapy improve the effect of external irradiation? A prospective, randomized study in central lung tumors. Int J Radiat Oncol Biol Phys 1997;38:533-40.
64. Hernandez P, Gyrsahaney A, Roman T, et al. High dose rate brachytherapy for the local control of endobronchial carcinoma following external irradiation. Thorax 1996;51:354-8.
65. de Ruysscher D, Vansteenkiste J. Chest radiotherapy in limited-stage small cell lung cancer: facts, questions, prospects. Radiother Oncol 2000;55:1-9.
66. Murray N, Coy P, Pater J, et al. Importance of timing for thoracic irradiation in the combined modality treatment of limited-stage small-cell lung cancer. The National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1993;11:336-44.
67. Turrisi AT, Kim K, Blum R, et al. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med 1999;340:265-71.
68. Sloan JA, Bonner JA, Hillman SL, et al. A quality-adjusted reanalysis of a phase III trial comparing once-daily thoracic radiation vs twice-daily thoracic radiation in patients with limited-stage small-cell lung cancer. Int J Radiat Oncol Biol Phys 2002;52:371-81.
69. Choi NC, Herndon JF, Rosenman J, et al. Phase I study to determine the maximum-tolerated dose of radiation in standard daily and hyperfractionated-accelerated twice-daily radiation schedules with concurrent chemotherapy for limited-stage small-cell lung cancer. J Clin Oncol 1998;16:3528-36.
70. Bremnes RM, Sundstrom S, Vilsvik J, et al. Multicenter phase II trial of paclitaxel, cisplatin and etoposide with concurrent radiation for limited-stage small-cell lung cancer. J Clin Oncol 2001;19:3532-8.
71. Jeremic B, Shibamoto Y, Nikolic N, et al. Role of radiation therapy in the combined-modality treatment of patients with extensive disease small-cell lung cancer: a randomized study. J Clin Oncol 1999;17:2092-9.
72. Suwinski R, Lee SP, Withers HR. Dose-response relationship for prophylactic cranial irradiation in small cell lung cancer. Int J Radiat Oncol Biol Phys 1998;40:797-806.
73. Blanke C, Ansari R, Mantravadi R, et al. Phase III trial of thoracic irradiation with or without cisplatin for locally advanced unresectable non-small cell lung cancer: a Hoosier Oncology Group protocol. J Clin Oncol 1995;13:1425-9.
74. Mornex F, Robinet G, Thomas P, et al. Sequential versus concurrent chemo-radiation (RT-CT) in locally advanced non small cell lung cancer (NSCLC): a French randomized phase III trial oF GLOT-GFPC (NPC 95-01 study). Eur J Cancer 2001;37(Suppl 6):S28.
75. Soresi E, Clerici M, Grilli R, et al. A randomized clinical trial comparing radiation therapy v radiation therapy plus cis-diachlorodiammine platinum (II) in the treatment of locally edvanced non-small cell lung cancer. Semin Oncol 1988;15 Suppl 7:20-5.
76. Schaake-Koning C, van den Bogaert W, Dalesio O, et al. Effects of concomitant cisplatin and radiotherapy on inoperable non-small cell lung cancer. N Engl J Med 1990;326:524-30.
77. Trovo MG, Minatel E, Franchin G, et al. Radiotherapy versus radiotherapy enhanced by cisplatin in stage III non-small cell lung cancer. Int J Radiat Oncol Biol Phys 1992;24:11-15.
78. Jeremic B, Shibamoto Y, Acimovic L, et al. Hyperfractionated radiation therapy with or without concurrent low-dose daily carboplatin/etoposide for stage III non-small cell lung cancer: a randomized study. J Clin Oncol 1996;14:1065-70.
79. Clamon G, Herndon JE, Cooper R, et al. Radiosenitization with carboplatin for patients with unresectable stage III non-small-cell lung cancer: a phase III trial of the Cancer and Leukaemia Group B and the Eastern Cooperative Oncology Group. J Clin Oncol 1999;17:4-11.
80. Ball D, Bishop J, Smith J, et al. A randomised phase III study of accelerated or standard fraction radiotherapy with or without concurrent carboplatin in inoerable non-small cell lung cancer: final report of an Australian multi-centre trial. Radiother Oncol 1999;52:129-36.